Pilot Precision Exercise Program for Lung Cancer Care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot tests the Precision Exercise Regimen for Cancer Care (PERCC), a virtually supervised, home-based program for patients with stage II–III non-small cell lung cancer receiving multimodal treatment. Participants begin exercise at least two weeks before their first neoadjuvant therapy and continue until about two months after surgery, with sessions delivered via telehealth. The program includes mobility, aerobic, and resistance exercises performed in varied postures and daily activities, with progression tailored to each participant. Feasibility outcomes focus on implementation, adherence, safety, and integration with routine care at the participating cancer centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ages 18 and older at time of diagnosis
* Patient diagnosed with stage II and III non-small cell lung cancer (NSCLC)
* Patient receives neoadjuvant therapy (defined as chemotherapy, radiation therapy immunotherapy, or any combination of these modalities) and surgery
* Patient able to follow direction and complete questionnaires in English or Spanish
* Patient agrees to complete the PERCC intervention

Exclusion Criteria:

* Morbidly obese (BMI \>40 kg/m2 ) or anorexic (BMI \<17.5 kg/m2 )
* Abnormalities on screening physical exam per study physicians or physical therapist to contraindicate participation in exercise program compliance
* Alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer)
* Patient scheduled to receive single modality cancer treatment (unimodal therapy), scheduled to begin treatment within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started

Where it's running

• University of Texas Medical Branch at Galveston
  Galveston, Texas, United States Recruiting
• Huntsman Cancer Institute
  Salt Lake City, Utah, United States Recruiting

Study contacts

• Principal investigator: Thomas Varghese, MD, MS, MBA, FACS — Huntsman Cancer Institute
• Study coordinator: Thomas Varghese, MD, MS, MBA, FACS
• Email: thomas.varghese@hsc.utah.edu
• Phone: 801-581-5311

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adaptive Chemotherapy for PD-L1 High Resectable NSCLC: A Chemo-PHREE Trial

  This study tests cemiplimab in adults with resectable non-small cell lung cancer to see if surgery can be pursued without preceding chemotherapy for some patients.

  Recruiting Phase 2 University of Maryland, Baltimore · Indianapolis, Indiana and 4 other locations · NCT07746388

• Anti-CTLA-4 plus sintilimab and chemotherapy before surgery for resectable Stage II–III NSCLC

  This trial will test whether adding an anti-CTLA-4 antibody (IBI310) to sintilimab plus chemotherapy before surgery helps people with PD-L1–negative, resectable Stage II–III non-small cell lung cancer.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07410975

• BIO 300 with thoracic radiation for early-stage non-small cell lung cancer and interstitial lung disease

  This trial will test whether adding BIO 300 to thoracic radiation lowers the chance of pneumonitis in people with stage I–II non-small cell lung cancer who also have interstitial lung disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07323732

• Testing Repotrectinib in Elderly and Frail Patients with Advanced NSCLC

  This study is testing a new cancer drug called repotrectinib to see if it helps older and frail patients with advanced lung cancer feel better and tolerate the treatment well.

  Recruiting at 20 sites Phase 2 Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Aix-en-Provence, Bouches Du Rhône and 19 other locations · NCT06552234

• Combining hormone therapy and immunotherapy for advanced lung cancer

  This study is testing if combining hormone therapy with a type of immunotherapy can help older men with advanced lung cancer respond better to treatment.

  Recruiting Jinzhou Medical University · Zhengzhou, Henan · NCT06512207

• Understanding the diagnosis and treatment of early and locally advanced non-small cell lung cancer

  This study looks at how patients with early and locally advanced non-small cell lung cancer are diagnosed and treated after surgery or radiation to see how well different approaches work.

  Recruiting at 7 sites MSD Italia S.r.l. · San Giovanni Rotondo, FG and 24 other locations · NCT06467383

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.